Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1No longer available 1

Sponsor Class

NIH 5OTHER 2NETWORK 2INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 18Tumor-Agnostic 7Gastrointestinal 4Lymphoid 3CNS 3Plasma cell 2Genitourinary 2Breast 2Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Granuloma, Plasma Cell 2

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 266Melphalan 211Calcium Dobesilate 188fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 42Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Crizotinib × Plasma cell × Clear all
NCT03874273 2019-03-14

Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
25 enrolled
Plasma cell

Granuloma, Plasma Cell

NCT03085186 2017-08-29

Treatment With Crizotinib Single Patient Expanded Access IND 134375

University of Pittsburgh

No longer available
Plasma cell

Granuloma, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡